

## Hepatitis C

### REFERENCES

- Abakumova OI, Kutsenko NG, et al. [Stimulation of regenerative processes and correction of the functional activity of the liver in its partial resection and toxic lesions]. *Vestn Ross Akad Med Nauk*. 1996;(5):36–41.
- al-Faleh FZ, Ramia S, et al. Profile of hepatitis C virus and the possible modes of transmission of the virus in the Gizan area of Saudi Arabia: A community-based study. *Ann Trop Med Parasitol*. 1995 Aug;89(4):431–7.
- Amarapurkar D. Natural history of hepatitis C virus infection. *J Gastroenterol Hepatol*. 2000 May;15 Suppl:E105–10.
- Bailon P, Palleroni A, et al. Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. *Bioconjug Chem*. 2001 Mar;12(2):195–202.
- Berkson BM. A conservative triple antioxidant approach to the treatment of hepatitis C. Combination of alpha lipoic acid (thioctic acid), silymarin, and selenium: Three case histories. *Med Klin (Munich)*. 1999 Oct 15;94 Suppl 3:84–9.
- Bottiglieri T, Hyland K, et al. The clinical potential of ademetionine (S-adenosylmethionine) in neurological disorders. *Drugs*. 1994 Aug;48(2):137–52.
- Boucher E, Bourienne A, et al. Liver iron concentration and distribution in chronic hepatitis C before and after interferon treatment. *Gut*. 1997 Jul;41(1):115–20.
- Centers for Disease Control and Prevention (CDC). Available at [http://www.cdc.gov/ncidod/dhqp/pdf/bbp/Exp\\_to\\_Blood.pdf](http://www.cdc.gov/ncidod/dhqp/pdf/bbp/Exp_to_Blood.pdf)
- Charlton M. Hepatitis C infection in liver transplantation. *Am J Transplant*. 2001 Sep;1(3):197–203.
- Christie JM, Chapman RW. Combination therapy for chronic hepatitis C: Interferon and ribavirin. *Hosp Med*. 1999 May;60(5):357–61.
- Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. *Hepatology*. 1997 Sep;26(3 Suppl 1):34S–8S.
- Dienstag JL. Sexual and perinatal transmission of hepatitis C. *Hepatology*. 1997 Sep;26(3 Suppl 1):66S–70S.
- Esteban JI, Gonzalez A, et al. Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis. *N Engl J Med*. 1990 Oct 18;323(16):1107–12.
- Fargion S, Fracanzani AL, et al. Liver iron influences the response to interferon alpha therapy in chronic hepatitis C. *Eur J Gastroenterol Hepatol*. 1997 May;9(5):497–503.
- Fong TL, Han SH, et al. A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C. *J Hepatol*. 1998 Mar;28(3):369–74.
- Fried MW, Shiffman ML, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med*. 2002 Sep 26;347(13):975–82.
- Gossrau R, Franz H. Histochemical response of mice to mistletoe lectin I (ML I). *Histochemistry*. 1990;94(5):531–7.
- Guyton KZ, Kensler TW. Prevention of liver cancer. *Curr Oncol Rep*. 2002 Nov;4(6):464–70.
- Hallberg L, Brune M, et al. Calcium: Effect of different amounts on nonheme- and heme-iron absorption in humans. *Am J Clin Nutr*. 1991 Jan;53(1):112–9.
- Harvey J, Colin-Jones DG. Mistletoe hepatitis. *Br Med J (Clin Res Ed)*. 1981 Jan 17;282(6259):186–7.

- Hernandez ME, Bruguera M, et al. Risk of needle-stick injuries in the transmission of hepatitis C virus in hospital personnel. *J Hepatol.* 1992 Sep;16(1-2):56–8.
- Holoman J, Glasa J, et al. [Positive effects of essential phospholipids and improvement of life style in patients with toxic liver injury]. *Bratisl Lek Listy.* 1998 Feb;99(2):75–81.
- Hoofnagle JH. Hepatitis C: The clinical spectrum of disease. *Hepatology.* 1997 Sep;26(3 Suppl 1):15S–20S.
- Ikeda M, Sugiyama K, et al. Lactoferrin markedly inhibits hepatitis C virus infection in cultured human hepatocytes. *Biochem Biophys Res Commun.* 1998 Apr 17;245(2):549–53.
- Ikeda M, Nozaki A, et al. Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells. *Virus Res.* 2000 Jan;66(1):51–63.
- Ishii K, Takamura N, et al. Long-term follow-up of chronic hepatitis C patients treated with oral lactoferrin for 12 months. *Hepatol Res.* 2003 Mar;25(3):226–33.
- Iwasaki M, Kanda D, et al. Absence of specific symptoms in chronic hepatitis C. *J Gastroenterol.* 2002;37(9):709–16.
- Jain SK, Pemberton PW, et al. Oxidative stress in chronic hepatitis C: Not just a feature of late stage disease. *J Hepatol.* 2002 Jun;36(6):805–11.
- Jankovic S. [Viral hepatitis C]. *Med Pregl.* 1999 Nov;52(11-12):459–63.
- Ko WS, Guo CH, et al. Blood micronutrient, oxidative stress, and viral load in patients with chronic hepatitis C. *World J Gastroenterol.* 2005 Aug 14;11(30):4697–702.
- Kolho E, Naukkarinen R, et al. Transmission of hepatitis C virus to sexual partners of seropositive patients with bleeding disorders: A rare event. *Scand J Infect Dis.* 1991;23(6):667–70.
- Kumada H. Long-term treatment of chronic hepatitis C with glycyrrhizin [stronger neo-minophagen C (SNMC)] for preventing liver cirrhosis and hepatocellular carcinoma. *Oncology.* 2002;62 Suppl 1:94–100.
- Lauer GM, Walker BD. Hepatitis C virus infection. *N Engl J Med.* 2001 Jul 5;345(1):41–52.
- Lieber CS. New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments. *Curr Gastroenterol Rep.* 2004 Feb;6(1):60–5.
- Martin-Vivaldi R, Noguera F, et al. Response of chronic hepatitis C to interferon-alpha treatment and relationship with iron metabolism. *Rev Esp Enferm Dig.* 1997 Jul;89(7):523–30.
- Mayer KE, Myers RP, et al. Silymarin treatment of viral hepatitis: A systematic review. *J Viral Hepat.* 2005 Nov;12(6):559–67.
- McHutchinson JG, Gordon SC, et al. Interferon alfa 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis. *N Engl J Med.* 1998;339(21):1485–92.
- Melhem A, Stern M, et al. Treatment of chronic hepatitis C virus infection via antioxidants: Results of a phase I clinical trial. *J Clin Gastroenterol.* 2005 Sep;39(8):737–42.
- Mitsui T, Iwano K, et al. Hepatitis C virus infection in medical personnel after needlestick accident. *Hepatology.* 1992 Nov;16(5):1109–14.
- Moriya K, Nakagawa K, et al. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. *Cancer Res.* 2001 Jun 1;61(11):4365–70.
- Murakami Y, Nagai A, et al. Vitamin E and C supplementation prevents decrease of eicosapentaenoic acid in mononuclear cells in chronic hepatitis C patients during combination therapy of interferon alpha-2b and ribavirin. *Nutrition.* 2006 Feb;22(2):114–22.
- Niederau C, Strohmeyer G, et al. Polyunsaturated phosphatidyl-choline and interferon alpha for treatment of chronic hepatitis B and

C: A multi-center, randomized, double-blind, placebo-controlled trial. *Hepatology*. 1998 May-Jun;45(21):797–804.

Oneta CM, Mak KM, et al. Dilinoleoylphosphatidylcholine selectively modulates lipopolysaccharide-induced Kupffer cell activation. *J Lab Clin Med*. 1999 Nov;134(5):466–70.

Puoti C, Pannullo A, et al. Ursodeoxycholic acid and chronic hepatitis C infection. *Lancet*. 1993 May 29;341(8857):1413–4.

Reddy KR, Wright TL, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. *Hepatology*. 2001 Feb;33(2):433–8.

Reizis AR, Malinovskaia VV, et al. [Effectiveness of using recombinant interferon alfa2 (reaferon) combined with antioxidants in children with acute hepatitis B]. *Pediatriia*. 1992;(1):60–4.

Sachithanandan S, Fielding JF. Low rate of hepatitis C transmission from women infected with contaminated anti-D immunoglobulin to their family contacts. *Ital J Gastroenterol Hepatol*. 1997 Feb;29(1):47–50.

Sharieff KA, Duncan D, et al. Advances in treatment of chronic hepatitis C: 'Pegylated' interferons. *Cleve Clin J Med*. 2002 Feb;69(2):155–9.

Sonnenbichler J, Zetl I. [Mechanism of action of silibinin. V. Effect of silibinin on the synthesis of ribosomal RNA, mRNA and tRNA in rat liver in vivo]. *Hoppe Seylers Z Physiol Chem*. 1984 May;365(5):555–66.

Sonnenbichler J, Goldberg M, et al. Stimulatory effect of Silibinin on the DNA synthesis in partially hepatectomized rat livers: Non-response in hepatoma and other malign cell lines. *Biochem Pharmacol*. 1986a Feb 1;35(3):538–41.

Sonnenbichler J, Zetl I. Biochemical effects of the flavonolignane silibinin on RNA, protein and DNA synthesis in rat livers. *Prog Clin Biol Res*. 1986b;213:319–31.

Swain RA, St Clair L. The role of folic acid in deficiency states and prevention of disease. *J Fam Pract*. 1997 Feb;44(2):138–44.

Thomas DL. Hepatitis C: Epidemiologic quandaries. *Clin Liver Dis*. 2001 Nov;5(4):955–68.

Tsai NC, Zuckerman E, et al. Effect of iron depletion on long-term response to interferon-alpha in patients with chronic hepatitis C who previously did not respond to interferon therapy. *Am J Gastroenterol*. 1997 Oct;92(10):1831–4.

Tsubota A, Kumada H, et al. Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: A randomized controlled trial in 170 patients. *Eur J Gastroenterol Hepatol*. 1999 Oct;11(10):1077–83.

Valenzuela A, Garrido A. Biochemical bases of the pharmacological action of the flavonoid silymarin and of its structural isomer silibinin. *Biol Res*. 1994;27(2):105–12.

Werner C, Wendel A. Hepatic uptake and antihepatotoxic properties of vitamin E and liposomes in the mouse. *Chem Biol Interact*. 1990;75(1):83–92.

Yi M, Kaneko S, et al. Hepatitis C virus envelope proteins bind lactoferrin. *J Virol*. 1997 Aug;71(8):5997–6002.

All Contents Copyright © 1995-2009 Life Extension Foundation All rights reserved.

**LifeExtension**<sup>®</sup>

These statements have not been evaluated by the FDA. These products are not intended to diagnose, treat, cure or prevent any disease. The information provided on this site is for informational purposes only and is not intended as a substitute for advice from your physician or other health care professional or any information contained on or in any product label or packaging. You should not use the information on this site for diagnosis or treatment of any health problem or for prescription of any medication or other treatment. You should consult with a healthcare professional before starting any diet, exercise or supplementation program, before taking any medication, or if you have or suspect you might have a health problem. You should not stop taking any medication without first consulting your physician.